Captrust Financial Advisors Viking Therapeutics, Inc. Transaction History

Captrust Financial Advisors

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	SELL	$2.11 - $3.15 $327 - $488	-155 Reduced 19.5%	640 $2,000
Q1 2022 May 16, 2022	BUY	$3.0 - $4.88 $2,385 - $3,879	795 New	795 $2,000
Q4 2021 Feb 14, 2022	SELL	$4.6 - $6.72 $837 - $1,223	-182 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$5.58 - $7.04 $1,015 - $1,281	182 New	182 $1,000
Q2 2021 Aug 16, 2021	SELL	$5.19 - $6.73 $1,089 - $1,413	-210 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$5.74 - $9.67 $1,205 - $2,030	210 New	210 $1,000

480

66.2M

6.24M

3.01M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $5.25B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.